Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from VRTX

5 Resilient Stocks to Buy for a Market Downturn

Yesterday, the broad market indices closed in negative territory on interest-rate-increase concerns. Goldman Sachs has predicted that the S&P might tumble to 3,600 this year if recessionary pressure persists. Non-cyclical stocks usually perform well during economic downturns. So, we believe Cardinal Health (CAH), Brookfield Infrastructure Corp. (BIPC), Smith & Nephew…

If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here's How Much You Would Have Today

If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here's How Much You Would Have Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.29% on an annualized basis producing an average annual return of 15.84%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.91 billion.

$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much

$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.35% on an annualized basis producing an average annual return of 15.26%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.63 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548. One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

3 Red-Hot Large-Cap Stocks Outpacing the S&P 500

Large-cap stocks are generally known to provide better safety to investors during periods of volatility. Therefore, we think Bristol-Myers Squibb (BMY), Vertex (VRTX), and Molina Healthcare (MOH), which have been outpacing the S&P 500, might be good investments now.

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.35% on an annualized basis.

5 Top-Rated Recession Resistant Stocks to Buy Immediately

Growing Western sanctions on Russia could cause further industrial supply disruptions. In addition, crude oil prices have been skyrocketing. Therefore, many analysts are forecasting the emergence of a recessionary environment. Given this backdrop, we think it could be wise to bet on defensive stocks Vertex Pharmaceuticals (VRTX), Ambev (ABEV), AmerisourceBergen…

inkl

Read news from The Economist, FT, and more,
with one subscription

4 Outperforming Growth Stocks to Buy in March

4 Outperforming Growth Stocks to Buy in March

The United States economy is growing strongly, outperforming other developed economies. Furthermore, analysts believe the country is well-positioned to weather economic challenges created by the Russia-Ukraine war. So, we think that growth stocks Vertex Pharmaceuticals (VRTX), Fair Isaac (FICO), Ralph Lauren (RL), and Exelixis (EXEL), which have outpaced the broader…

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.

Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance

Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) posted

Recap: Vertex Pharmaceuticals Q4 Earnings

Recap: Vertex Pharmaceuticals Q4 Earnings

Vertex Pharmaceuticals (NASDAQ:VRTX) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

3 Biotech Stocks Poised to Outperform in 2022

3 Biotech Stocks Poised to Outperform in 2022

With COVID-19 mutating into newer, more transmissible variants, biotechnology stocks have the potential to again outperform as authorities worldwide redouble their efforts at mass vaccinations. So, we think it could be wise to now add quality biotech stocks Vertex Pharmaceuticals (VRTX), BioNTech SE (BNTX), and Incyte (INCY) to one’s watchlist.…

Where Vertex Pharmaceuticals Stands With Analysts

Where Vertex Pharmaceuticals Stands With Analysts

Over the past 3 months, 6 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1 2 3 4 5

Organisations

BristolMyers Squibb Company

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

375,045 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play